Skip to main content

Table 6 Additional areas of interest within mesothelioma immunotherapy

From: Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

Outstanding areas of interest for immunotherapy in MPM
1 Can we combine Tumor-Treating Fields (TTF) with checkpoint inhibitors?
2 How can we best stratify patients to checkpoint inhibitors?
3 Is there any utility for the use of PD-L1 expression as a biomarker to direct therapy?
4 Can we epigenetically prime MPM for checkpoint inhibitor therapy?
5 Can we use BAP1 status in immunotherapy of MPM?
6 Would targeting Toll Like Receptors (TLRs) along with checkpoint inhibitors prove beneficial?
7 What is the best way to monitor response to checkpoint inhibitors?
8 Is the cost prohibitive for the use of checkpoint inhibitors in the second-line/salvage setting?